Meanwhile, an aggressive subset of prostate cancer patients will become resistant to ADT therapies and develop therapy‐induced t‐NEPC,32 with unique features of AR loss and expression of neuroendocrine lineage markers. The gene discussed is AR; the disease is prostate carcinoma.